DMX-200
Focal Segmental Glomerulosclerosis (FSGS)
Key Facts
Indication
Focal Segmental Glomerulosclerosis (FSGS)
Phase
Phase 3
Status
Active
Company
About Amicus Therapeutics
Amicus Therapeutics is a fully integrated, global biotech with a mission to address the vast unmet need in rare diseases, where 95% of over 10,000 known conditions lack approved treatments. The company has achieved commercial success with two approved therapies for Fabry and Pompe disease, validating its dual-technology platform. Its strategy centers on deepening its impact in core lysosomal disorders, expanding into adjacent rare diseases like FSGS, and maintaining a patient-centric culture that drives innovation and operational execution.
View full company profileTherapeutic Areas
Other Focal Segmental Glomerulosclerosis (FSGS) Drugs
| Drug | Company | Phase |
|---|---|---|
| KRP-205 | Kissei Pharmaceutical | Phase II |
| Sparsentan | Travere Therapeutics | Phase 3 |
| Voclosporin | Aurinia Pharmaceuticals | Phase 2 |